Blog

Blog

  • Keystone Heart is pleased to share the results from REFLECT Phase II: A Randomized Trial of a Cerebral Embolic Protection Device During Transcatheter Aortic Valve Replacement (TAVR) have been accepted for presentation in a late-breaking clinical science session at the upcoming Cardiovascular Research Foundation TCT......

  • The transcatheter aortic valve replacement (TAVR) has become an established and widely adopted treatment for patients who are under the risk of calcific aortic valve stenosis. With the advancements in medical technology, the TAVR procedure has rapidly evolved in recent years. Earlier, TAVR was considered......

Triguard

The Only CE Marked Cerebral Embolic Protection Device Designed to Cover all Three Major Aortic Vessels.

Cerebral Embolic Protection Device

VISIT Careers PAGE

Skip to content